Annotation Detail

Information
Associated Genes
MGMT
Associated Variants
MGMT UNDEREXPRESSION ( ENST00000306010.8 )
MGMT UNDEREXPRESSION ( ENST00000306010.8 )
Associated Disease
neuroendocrine tumor
Source Database
CIViC Evidence
Description
Among those patients who received temozolomide-based therapy in this study, the median progression-free survival for patients whose tumors showed intact MGMT expression was 9.3 months compared with 19.2 months for patients with MGMT-deficient tumors (P = 0.11). The median overall survival for patients whose tumors showed intact MGMT expression was 19.1 months; the median overall survival for patients with MGMT deficient tumors was not reached.
Variant Origin
N/A
Variant Origin
N/A
Evidence URL
https://civic.genome.wustl.edu/links/evidence_items/2904
Gene URL
https://civic.genome.wustl.edu/links/genes/34
Variant URL
https://civic.genome.wustl.edu/links/variants/1255
Rating
2
Evidence Type
Predictive
Disease
Neuroendocrine Tumor
Evidence Direction
Supports
Drug
Temozolomide
Evidence Level
B
Clinical Significance
Sensitivity/Response
Pubmed
19118063
Drugs
Drug NameSensitivitySupported
TemozolomideSensitivitytrue